Review of Cornea





Become a fan on Facebook Follow us on Twitter

Limbal Stem Cells Cure Blindness

Staff

7/15/2010

Some 75% of patients with severe corneal damage were successfully healed with transplants of their own limbal stem cells, according to a study published online in the New England Journal of Medicine.

Researchers in Italy used a small number of stem cells from the patient’s fellow eye, multiplied them in the lab and placed them on the damaged eye. They grew new corneal tissue to replace the damage. This treatment was a success in 82 of 113 eyes and a partial success in 14 eyes. Failures (11 eyes) all occurred within the first year post-graft, and results did not decrease acuity beneath baseline.

Patients’ limbal stem cell deficiency was caused by chemical burn (103), thermal burn (7), bacterial infection (2) and orbital irradiation (1). Of the total cohort, 84% of patients had undergone corrective surgery; all of these had failed. Patients ranged in age from 14 to 80, and the duration between injury and graft during the study ranged from 0.8 years to 56.4 years.



This patient presented with limbal stem cell deficiency due to Stevens-Johnson syndrome. Conjunctival limbal autograft from the fellow eye resulted in a healed, smooth corneal surface with no immunosuppression.
Photos: Scheffer Tseng, M.D., Ph.D.

Patients’ improvement was stable throughout the decade-long study. Complications included hemorrhage, residual fibrin on the third day post-op, inflammation, blepharitis with epithelial involvement and herpetic keratitis. All of these were treated successfully with standard therapy. A successful graft regenerated normal avascular corneal epithelium, but vision was only attainable if the original injury had not damaged the corneal stroma.

For those eyes with stromal scarring, corrective surgery one to two years post-graft—penetrating keratoplasty, lamellar keratoplasty or phototherapeutic keratectomy—replaced the damaged stroma.

Researchers saw no intraoperative complications and followed standard postoperative therapeutic protocols with normal results. After refractive surgery, permanent recovery of 0.6 (~20/32) to 1.0 (20/20) visual acuity was seen in 21 patients, and the other 25 gained up to 0.5 (20/40) visual acuity.

This treatment would most benefit patients with corneal chemical burns, say researchers. But, they add, it would not work for patients with damage to the optic nerve or macular degeneration, or for those patients who are completely blind in both eyes—doctors need at least some healthy tissue to transplant. And, an additional benefit of such stem cell autografts is that the patient does not need to take anti-rejection drugs. (For more on stem cell therapy for limbal stem cell deficiency, see “ Stem Cells to the Rescue.”)

Rama P, Matuska S, Paganoni G, et al. Limbal stem-cell therapy and long-term corneal regeneration. New Engl J Med. 2010 Jun 23. [Epub ahead of print]



Optometric Retina Society

Optometric Retina Society Newsletter aims to provide clinical updates in retinal disease for primary care optometrists. As part of this mission, the ORS organizes both annual meetings and a quarterly e-newsletter, through which the latest research and clinical findings are presented to attendees and readers.

To subscribe to the Optometric Retina Society quarterly e-newsletter and receive it via e-mail, click here.

Optometric Glaucoma  Society

Optometric Glaucoma Society Newsletter strives to promote excellence in the care of patients with glaucoma through professional education and scientific investigation. Its objectives are to promote the education of health care professionals, to promote glaucoma research, to make this information accessible to health care professionals and the public, and to establish collaboration with other professional organizations.

To subscribe to the E-Journal of the Optometric Glaucoma Society and receive it via e-mail, click here.

Optometric Glaucoma  Society

Optometric Physician Newsletter is a weekly e-journal edited by Art Epstein, O.D. It began in 2001 and discusses current optometric issues, research and industry news.

To subscribe to OP and receive it via e-mail, click here.

Classifieds | Patient Handouts | Optometric Study Center | Editorial Staff | Business Staff | Media Kit | Contact | Privacy Policy | Subscribe